Market Research Logo

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.

Over the recent years, the Psoriasis Drugs market is growing rapidly due to rising prevalence of Psoriasis patients around the world. Globally, the growth of Psoriasis Drugs market is driven by rising psoriatic population. The global psoriasis drugs market is projected to display a robust growth during 2019– 2023, chiefly driven by low efficacy and tolerability of present psoriasis drugs and improved safety and efficacy of investigational drugs.

Scope of the Report

Psoriasis Pipeline Drugs Assessment – Drug X1, X2, X3, X4, X5, X6 (Forecast Period: 2019-2023)

  • Market Potential
  • Clinical Trials
  • Product Description
  • Regulatory Phases
  • 7Ps Analysis
Country Analysis – US, UK, France, Italy, Spain, Germany and Norway (Forecast Period: 2019-2023)
  • Incidence of Psoriasis
Other Report Highlights
  • Company Analysis – UCB, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim, Forward Pharma, Almirall and Valeant Pharmaceuticals


1. Research Methodology
2. Psoriasis - An Overview
2.1. Symptoms of Psoriasis
2.2. Types of Psoriasis
2.3. Causes of Psoriasis
2.4. Triggers, Risk Factors and Complications of Psoriasis
3. Diagnosis of Psoriasis
4. Treatment of Psoriasis
5. Anti-Psoriasis Pipeline Drugs
5.1. Anti-Psoriasis Pipeline Drugs – Cimzia (Certolizumab Pegol)
5.1.1. Description
5.1.2. Regulatory Milestones
5.1.3. Advantages & Disadvantages
5.1.4. Product Profile & Launch Date
5.1.5. Clinical Trials and Status
5.1.6. Pivotal Clinical Trials and Results
Table 1: Response rate of patients who achieved PASI at week 16 in CIMPASI-1 & CIMPASI-2
Table 2: Rate of patients achieving at least a two-point improvement to a final score of clearance or almost clear skin on PGA Scale at week 16 in CIMPASI-1 & CIMPASI-2
Table 3: Response rate of patients who achieved PASI 75 at week 12 in CIMPACT
Table 4: Response rate of patients who achieved PASI 75 at week 16 in CIMPACT
Table 5: Response Rate of patients achieving at least a two-point improvement to a final score of clearance or almost clear skin on PGA Scale at week 16 in CIMPACT
5.1.7. Cimzia (Certolizumab Pegol) – Global Market Potential
Table 6: Global Cimzia Market Size, By Value, Forecast, 2019-2023 (USD million)
5.1.8. Cimzia (Certolizumab Pegol) – 7Ps Analysis
5.2. Anti-Psoriasis Pipeline Drugs – Tildrakizumab (MK-3222)
5.2.1. Description
5.2.2. Regulatory Milestones
5.2.3. Advantages & Disadvantages
5.2.4. Product Profile & Launch Date
5.2.5. Clinical Trials and Status
5.2.6. Pivotal Clinical Trials and Results
Table 7: Response rate of patients in 100mg dose regimen
Table 8: Response rate of patients in 200mg dose regimen
5.2.7. Tildrakizumab (MK-3222)– Global Market Potential
Table 9: Global Tildrakizumab (MK-3222) Market Size, By Value, Forecast, 2019-2023 (USD million)
5.2.8. Tildrakizumab (MK-3222)– 7Ps Analysis
5.3. Anti-Psoriasis Pipeline Drugs – Risankizumab (BI 655066)
5.3.1. Description
5.3.2. Regulatory Milestones
5.3.3. Advantages & Disadvantages
5.3.4. Product Profile & Launch Date
5.3.5. Clinical Trials and Status
5.3.6. Pivotal Clinical Trials and Results
Table 10: Response rate of patients in ultiMMa-1 (at wee 16)
Table 11: Response rate of patients in ultiMMa-2 (at week 16)
Table 12: Response rate of patients in ultiMMa-1 (at 1 year)
Table 13: Response rate of patients in ultiMMa-2 (at 1 year)
Table 14: Response rate of patients in IMMvent (at week 16)
Table 15: Response rate of patients in IMMhance (at week 16)
5.3.7. Risankizumab (BI 655066)– Global Market Potential
Table 16: Global Risankizumab (BI 655066) Market Size, By Value, Forecast, 2019-2023 (USD million)
5.3.8. Risankizumab (BI 655066)– 7Ps Analysis
5.4. Anti-Psoriasis Pipeline Drugs – FP187
5.4.1. Description
5.4.2. Regulatory Milestones
5.4.3. Advantages & Disadvantages
5.4.4. Product Profile & Launch Date
5.4.5. Clinical Trials and Status
5.4.6. Pivotal Clinical Trials and Results
Table 17: Percent of Patients achieving PASI75 in 500mg dose arm (at week 20)
Table 18: Percent of Patients achieving PASI75 in 750mg dose arm (at week 20)
Table 19: Percent of Patients achieving PASI75 open label up-titration treatment arm, 750mg dose (at week 20)
5.4.7. FP187 – Global Market Potential
Table 20: FP-187 Market Size, By Value, Forecast, 2019-2023 (USD million)
5.4.8. FP187 – 7Ps Analysis
5.5. Anti-Psoriasis Pipeline Drugs – Skilarence (LAS41008)
5.5.1. Description
5.5.2. Regulatory Milestones
5.5.3. Advantages & Disadvantages
5.5.4. Product Profile & Launch Date
5.5.5. Clinical Trials and Status
5.5.6. Pivotal Clinical Trials and Results
Table 21: Response rate of patients achieving PASI 75 at week 16
5.5.7. Skilarence (LAS41008) – Global Market Potential
Table 22: Global Skilarence (LAS41008) Market Size, By Value, Forecast, 2021-2023 (USD million)
5.5.8. Skilarence (LAS41008) – 7Ps Analysis
5.6. Anti-Psoriasis Pipeline Drugs – Duobrii (IDB 118)
5.6.1. Description
5.6.2. Regulatory Milestones
5.6.3. Advantages & Disadvantages
5.6.4. Product Profile & Launch Date
5.6.5. Clinical Trials and Status
5.6.6. Pivotal Clinical Trials and Results
Table 23: Percentage of success (IGA 0/1) at week 8
5.6.7. Duobrii (IDB 118) – Global Market Potential
Table 24: Global IDP-118 Market Size, By Value, Forecast, 2019-2023 (USD million)
5.6.8. Duobrii (IDB 118) – 7Ps Analysis
6. Company Profiles
6.1. UCB
Table 25: UCB Company Revenues, By Value, in million USD
Table 26: UCB net sales, by value, in million USD
Table 27: UCB net sales by geography, by value, in million USD
Table 28: UCB net sales in 2016, by geography
6.2. Sun Pharmaceutical Industries Ltd
6.3. Boehringer Ingelheim
6.4. Forward Pharma
6.5. Almirall
6.6. Valeant Pharmaceuticals
7. Number of Psoriasis Patients By Country
7.1. U.S
Table 29: Number of Psoriasis Patients in U.S, 2012-2016 (in million)
7.2. U.K
Table 30: Number of Psoriasis Patients in U.K, 2012-2016 (in million)
7.3. France
Table 31: Number of Psoriasis Patients in France, 2012-2016 (in million)
7.4. Italy
Table 32: Number of Psoriasis Patients in Italy, 2012-2016 (in million)
7.5. Germany
Table 33: Number of Psoriasis Patients in Germany, 2012-2016 (in million)
7.6. Norway
Table 34: Number of Psoriasis Patients in Norway, 2012-2016 (in million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report